NEW BRUNSWICK, N.J. ( TheStreet) -- A Johnson & Johnson ( JNJ) unit received an offer for its breast-care business from private-equity firm GTCR Golder Rauner's Devicor unit for an undisclosed amount, a report says.

The unit has been weighing a possible sale of the division to focus on areas with higher growth potential. "We believe this offer demonstrates commitment from Devicor and GTCR to develop the breast-care business to its full potential," Ethicon Endo-Surgery Chairman Karen Licitra told the Wall Street Journal.

The J&J unit has until June 15 to accept the "irrevocable, unconditional" offer. If it receives regulatory approval, the deal would be expected to close by the third quarter and the breast-care unit's employees are expected to transfer to Devicor, the Journal reports.

Ethicon sells products designed to help diagnose breast cancer in its early stages. The division's products include breast-biopsy and tissue markers as well as marketing and distribution rights for the division's Neoprobe gamma detection systems, the Journal reports.

Follow TheStreet.com on Twitter and become a fan on Facebook.

More from Stocks

Dow Futures Tank as Trade War Fears Grip Wall Street

Dow Futures Tank as Trade War Fears Grip Wall Street

Why GE's Stock Has Fallen 9% in the Last 30 Days

Why GE's Stock Has Fallen 9% in the Last 30 Days

5 Stock Picks Under $10 for Millennials

5 Stock Picks Under $10 for Millennials

3 Complicated Investing Strategies Millennials Love

3 Complicated Investing Strategies Millennials Love

Tyson Foods CEO: We Aren't Done Making Deals

Tyson Foods CEO: We Aren't Done Making Deals